Search Results - "Shimokawa, M"

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer by Yoshioka, H., Shimokawa, M., Seto, T., Morita, S., Yatabe, Y., Okamoto, I., Tsurutani, J., Satouchi, M., Hirashima, T., Atagi, S., Shibata, K., Saito, H., Toyooka, S., Yamamoto, N., Nakagawa, K., Mitsudomi, T.

“…Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the…”
Get full text

A new method for measurement of placental elasticity: Acoustic radiation force impulse imaging by Sugitani, M, Fujita, Y, Yumoto, Y, Fukushima, K, Takeuchi, T, Shimokawa, M, Kato, K

“…Abstract Introduction The velocities of the lateral shear waves (Vs; m s−1 ) generated by an acoustic radiation force impulse (ARFI) correlate with Young's…”
Get full text

Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection by Itoh, S., Yugawa, K., Shimokawa, M., Yoshiya, S., Mano, Y., Takeishi, K., Toshima, T., Maehara, Y., Mori, M., Yoshizumi, T.

“…Background Cancer‐related inflammation has been correlated with cancer prognosis. This study evaluated inflammatory biomarkers, including…”
Get full text

Randomized phase II multicenter study comparing modified PFE regimen with modified TPEx regimen in recurrent or metastatic squamous cell carcinoma of the head and neck: TEMPER study by Shimokawa, M., Suzuki, M., Sugasawa, M., Shiga, K., Satoh, T., Inohara, H.

Get full text

Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study by Shimokawa, M., Nosaki, K., Seto, T., Ohashi, K., Morise, M., Fujiwara, Y., Sakakibara, J., Murakami, H., Yano, S., Satouchi, M., Matsumoto, S., Goto, K., Yoh, K.

Get full text

A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study by Nakazawa, J., Otsuka, T., Shimokawa, M., Koga, F., Ueda, Y., Otsu, S., Arima, S., Fukahori, M., Makiyama, A., Taguchi, H., Honda, T., Shibuki, T., Shirakawa, T., Mitsugi, K., Nio, K., Ide, Y., Ureshino, N.

Get full text

Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B by Yuki, S., Shinozaki, K., Kashiwada, T., Kusumoto, T., Iwatsuki, M., Satake, H., Tokunaga, S., Emi, Y., Makiyama, A., Kawamoto, Y., Komatsu, Y., Shimokawa, M., Saeki, H., Oki, E., Baba, H., Maehara, Y.

Get full text

Elevation of serum KL-6 in patients with psoriasis treated with anti-tumour necrosis factor-[alpha] therapy by Higashi, Y, Tada, K, Shimokawa, M, Kawai, K, Kanekura, T

“…Summary We report three patients with psoriasis whose serum level of Krebs Von Den Lungen (KL)-6 increased during therapy with anti-tumour necrosis factor…”
Get full text

Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy by Takada, K., Takamori, S., Shimokawa, M., Toyokawa, G., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya-Kawano, Y., Otsubo, K., Inoue, K., Yoneshima, Y., Tanaka, K., Okamoto, I., Nakanishi, Y., Mori, M.

“…The albumin-bilirubin (ALBI) grade is a novel indicator of the liver function. Some studies showed that the ALBI grade was a prognostic and predictive…”
Get full text

Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study by Kawakami, T, Yamazaki, K, Oki, E, Shimokawa, M, Takahashi, N, Yokota, M, Tokunaga, S, Esaki, T, Gamoh, M, Maeda, A, Tsuji, Y, Sakai, A, Hatanaka, K, Shimada, Y, Shiozawa, M, Komatsu, Y, Okuda, H, Ohue, M, Maehara, Y

Get full text

Phase II study of S-1 and oxaliplatin as neo-adjuvant chemotherapy for locally advanced gastric and esophago-gastric cancer (KSCC1601) by Kobayashi, K., Iwatsuki, M., Orita, H., Hidaka, S., Arigami, T., Kusumoto, T., Satake, H., Oki, E., Satoshi, K., Tobimatsu, K., Shimokawa, M., Saeki, H., Makiyama, A., Kakeji, Y., Natsugoe, S., Baba, H., Eguchi, S., Maehara, Y.

Get full text

A PHASE 2 TRIAL OF CHOP WITH ANTI‐CCR4 ANTIBODY MOGAMULIZUMAB FOR ELDERLY PATIENTS WITH CCR4‐POSITIVE ADULT T‐CELL LEUKEMIA/LYMPHOMA by Utsunomiya, A., Kusumoto, S., Choi, I., Yoshimitsu, M., Shimokawa, M., Suehiro, Y., Hidaka, T., Nosaka, K., Sasaki, H., Rai, S., Tamura, S., Owatari, S., Koh, K., Hidaka, M., Kato, T., Jo, T., Moriuchi, Y., Ogata, M., Ohtsuka, E., Suzushima, H., Ito, S., Yoshida, S., Ito, A., Nakamura, D., Tokunaga, M., Sekine, M., Sakamoto, Y., Inagaki, H., Ishida, T., Ishitsuka, K.

Get full text

Correlation of progression-free and post-progression survival with overall survival in phase III trials of first-line chemotherapy for advanced epithelial ovarian cancer by Shimokawa, M, Ohki, M, Kaku, T

“…The authors examined the relation between post-progression survival (PPS) and overall survival (OS) in phase III trials of first-line chemotherapy for advanced…”
Get more information

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy by Shimokawa, Mototsugu, Takada, Kazuki, Toyokawa, Gouji, Takamori, Shinkichi, Mizuki, Fumitaka, Takenaka, Tomoyoshi, Hayashi, Toshinobu

“…Purpose: The incidence of delayed chemotherapy-induced nausea and vomiting (CINV) in patients with non-small cell lung cancer (NSCLC) receiving carboplatin…”
Get full text

Elevation of serum KL-6 in patients with psoriasis treated with anti-tumour necrosis factor-α therapy by Higashi, Y., Tada, K., Shimokawa, M., Kawai, K., Kanekura, T.

“…Summary We report three patients with psoriasis whose serum level of Krebs Von Den Lungen (KL)‐6 increased during therapy with anti‐tumour necrosis factor…”
Get full text

P-055Prospective evaluation for chemotherapy-induced nausea and vomiting in colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic risk by Shimokawa, M, Hayashi, T, Kogawa, T, Matsui, R, Suzuki, K, Saeki, T, Aiba, K, Tamura, K

Get full text

A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer by Harada, T, Hamada, A, Shimokawa, M, Takayama, K, Kudoh, S, Maeno, K, Saeki, S, Miyawaki, H, Moriyama, A, Nakagawa, K, Nakanishi, Y

“…This study reports the findings of a Phase I/II, cohort, dose-escalation trial of amrubicin and irinotecan with the support of granulocyte colony-stimulation…”
Get full text

1601 The multicenter, prospective observational study of the 5-HT3 receptor antagonist and dexamethasone as prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in moderately emetic chemotherapy (MEC) for solid tumors by Sugita, K, Matsui, R, Suzuki, K, Takiguchi, T, Nishio, M, Koike, T, Hayashi, T, Seto, T, Kogure, Y, Nogami, N, Fujiwara, K, Kaneda, H, Harada, T, Shimizu, S, Kimura, M, Kenmotsu, H, Shimokawa, M, Goto, K

Get full text

Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer by Kogawa, T., Doi, A., Shimokawa, M., Fouad, T. M., Osuga, T., Tamura, F., Mizushima, T., Kimura, T., Abe, S., Ihara, H., Kukitsu, T., Sumiyoshi, T., Yoshizaki, N., Hirayama, M., Sasaki, T., Kawarada, Y., Kitashiro, S., Okushiba, S., Kondo, H., Tsuji, Y.

“…Cetuximab-containing treatments for metastatic colorectal cancer have been shown to have higher overall response rates and longer progression-free and overall…”
Get full text

A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma by Shimokawa, Mototsugu, Hasegawa, Seiki, Fukuoka, Kazuya, Okada, Morihito, Yokoi, Kohei, Tanaka, Fumihiro, Yamanaka, Takeharu, Daimon, Takashi, Nakano, Takashi

“…A prospective multi-institutional study has been initiated in Japan to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin,…”
Get full text